Building trust in uncharted territory: Patient considerations for embracing Cell and Gene Therapies
Watch a presentation by Patrick Collins, MA, Vice President of Corporate Relations at the National Organization for Rare Disorders (NORD) as he explores the critical patient considerations surrounding the adoption of cell and gene therapies (CGTs), focusing on trust and insurance barriers that impact patient access.
Key Insights
In this presentation, Collins addresses the complexities of building trust and ensuring accessibility for patients considering CGT:
- Patient trust in innovative therapies: While the allure of potentially curative treatments is enticing, many patients face the uncertainty of venturing into uncharted territory. The lack of long-term efficacy data poses challenges, as trust is typically built over time through positive patient experiences and outcomes.
- Building Confidence Through Communication: This presentation discusses the importance of patient testimonials and word-of-mouth endorsements in establishing confidence in new therapies. The need for ongoing post-marketing surveillance is highlighted as a way to enhance trust and ensure safety in the long term.
- Insurance coverage and reimbursement challenges: The presentation delves into the pressing question of whether cell and gene therapies will be adequately covered by insurance. The high costs associated with these innovative treatments and the potential reluctance of payers to cover them as more therapies enter the market is highlighted.
- Value-based arrangements: A key focus is the exploration of new reimbursement models, such as value-based arrangements, which may provide greater flexibility for insurers and ensure that patients have access to potentially curative therapies without prohibitive costs.
- Navigating the hurdles: Collins emphasizes the need for patients and providers to navigate a complex landscape of formularies and other insurance hurdles to ensure access to CGTs. He calls for collaboration among stakeholders to overcome these challenges and streamline access.
Watch the full recording for a comprehensive understanding of patient considerations in the realm of cell and gene therapies. Fill out the form below to discover how building trust and addressing reimbursement challenges are crucial for the successful adoption of these transformative therapies.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.